Carcinoma, Transitional Cell
Information
- Disease name
- Carcinoma, Transitional Cell
- Disease ID
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT04660929 | Active, not recruiting | Phase 1 | CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors | February 2, 2021 | December 31, 2024 |
| NCT03288545 | Active, not recruiting | Phase 1/Phase 2 | A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer | October 11, 2017 | December 31, 2026 |
| NCT00101842 | Completed | Phase 1/Phase 2 | Gemcitabine and Platinol Followed by Pemetrexed and Gemcitabine in Patients With Advanced or Metastatic Bladder Cancer | December 2004 | July 2006 |
| NCT00001381 | Completed | Phase 1 | A Phase I Trial Using Suramin to Treat Superficial Transitional Cell Carcinoma of the Bladder | March 1994 | December 2000 |
| NCT00077688 | Completed | Phase 2 | TOCOSOL(TM) Paclitaxel in Metastatic or Locally Advanced Unresectable Transitional Cell Carcinoma of the Urothelium | November 2003 | September 2007 |
| NCT01478685 | Completed | Phase 1 | A Phase 1 Study of CC-486 as a Single Agent and in Combination With Carboplatin or ABI-007 in Subjects With Relapsed or Refractory Solid Tumors | November 29, 2011 | November 17, 2015 |
| NCT01529411 | Completed | Phase 2 | Clinical Trial With Vinflunine as Maintenance Therapy in Metastatic Urothelial Cancer | February 2012 | December 2014 |
| NCT02014337 | Completed | Phase 1 | Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors | January 2014 | December 2017 |
| NCT02300610 | Completed | Phase 1 | Enzalutamide in Combination With Gemcitabine and Cisplatin in Bladder Cancer | February 11, 2015 | April 19, 2019 |
| NCT02443324 | Completed | Phase 1 | A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer | July 29, 2015 | April 12, 2022 |
| NCT02451423 | Completed | Phase 2 | Neoadjuvant Atezolizumab in Localized Bladder Cancer | March 29, 2016 | March 31, 2023 |
| NCT02793128 | Completed | Phase 3 | The OLYMPUS Study - Optimized DeLivery of Mitomycin for Primary UTUC Study | April 4, 2017 | March 5, 2020 |
| NCT03051373 | Completed | Phase 2 | Phase 2 Trial of Nab-paclitaxel Plus S-1 vs Gemcitabine Plus Cisplatin as 1-line Chemotherapy of Patients With Local Advanced and/or Metastatic Transitional Cell Carcinoma of Urothelial Tract | April 1, 2017 | April 30, 2020 |
| NCT03219333 | Completed | Phase 2 | A Study of Enfortumab Vedotin for Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer | October 8, 2017 | July 28, 2023 |
| NCT03410693 | Completed | Phase 2/Phase 3 | Study of Rogaratinib (BAY1163877) vs Chemotherapy in Patients With FGFR (Fibroblast Growth Factor Receptor)-Positive Locally Advanced or Metastatic Urothelial Carcinoma | May 31, 2018 | October 27, 2020 |
| NCT00191971 | Completed | Phase 2 | 2nd Line Gemcitabine Monotherapy for Transitional Cell Carcinoma of Urothelium (TCC) After CDDP Regimen | January 2004 | September 2006 |
| NCT00722553 | Completed | Phase 2 | Study of Pralatrexate to Treat Advanced or Metastatic Relapsed Transitional Cell Carcinoma of the Urinary Bladder | July 2008 | September 2011 |
| NCT05874921 | Recruiting | uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto | November 17, 2023 | January 2028 | |
| NCT05318339 | Recruiting | Phase 2 | A Study of Trastuzumab and Pyrotinib in HER2 Positive Locally Advanced or Metastatic Urothelial Carcinoma | March 10, 2022 | December 10, 2024 |
| NCT00127595 | Terminated | Phase 2 | Oxaliplatin With Gemcitabine in Patients With Carcinoma of the Urothelial Tract | January 2002 | April 2005 |
| NCT04039867 | Terminated | Phase 2 | Evaluation of Oxaliplatin and Gemcitabine in Patients With Metastatic Bladder Cancer | January 20, 2005 | October 6, 2011 |
| NCT02450331 | Terminated | Phase 3 | A Study of Atezolizumab Versus Observation as Adjuvant Therapy in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (UC) After Surgical Resection | October 5, 2015 | June 14, 2022 |
| NCT01215877 | Unknown status | Phase 2 | Tesetaxel for Previously Treated Patients With Bladder Cancer | September 2010 | December 2012 |
| NCT01189838 | Unknown status | The Expression and Effect of Cyr61 in Urinary Tract Transitional Cell Carcinoma | January 2010 | December 2010 | |
| NCT00146276 | Unknown status | Phase 3 | Adjuvant Versus Progression-Triggered Gemcitabine Monotherapy for Locally Advanced Bladder Cancer | July 2000 | |
| NCT00109655 | Unknown status | Phase 1 | Dose-Escalation Study of CG0070 for Bladder Cancer After BCG (Bacillus Calmette-Guerin) Failure | April 2005 | September 2010 |
| NCT00172367 | Withdrawn | Phase 2 | Chemoprevention Trial for Uremia-Associated Urothelial Carcinoma | January 2006 |
- MeSH unique ID (MeSH (Medical Subject Headings))
- D002295